Search research articles
Contact Us
Filters
Showing results (31-40 of 87) with videos related to
Page
of 9
Sort By:
Chemical Reviews
|
January 15, 2019
Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Reece G Kenny, Celine J Marmion
The British Journal of Ophthalmology
|
February 1, 1976
A clinical evaluation of the applanation pneumatonograph
M R Jain, V J Marmion
Journal of Neural Transmission (Vienna, Austria : 1996)
|
April 24, 2017
α-Synuclein nonhuman primate models of Parkinson's disease
David J Marmion, Jeffrey H Kordower
Journal of the Royal Society of Medicine
|
May 2, 2002
The death of Claudius
V J Marmion, T E J Wiedemann
Modern Problems in Ophthalmology
|
January 1, 1976
Genetic correlation of diabetic exudative retinopathy
V J Marmion, S Yurdakul, E A Keely
Chemical Communications (Cambridge, England)
|
November 4, 2009
A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity
Darren Griffith, Maria P Morgan, Celine J Marmion
Anti-Cancer Agents in Medicinal Chemistry
|
April 13, 2010
Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics
Darren Griffith, James P Parker, Celine J Marmion
Journal of Neural Transmission (Vienna, Austria : 1996)
|
October 6, 2021
A historical review of multiple system atrophy with a critical appraisal of cellular and animal models
David J Marmion, Wouter Peelaerts, Jeffrey H Kordower
Chemical Communications (Cambridge, England)
|
September 21, 2002
Ruthenium(III) readily abstracts NO from L-arginine, the physiological precursor to NO, in the presence of H2O2. A remarkably simple model system for NO synthases
C J Marmion, T Murphy, K B Nolan
Metallomics : Integrated Biometal Science
|
November 17, 2015
Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer
James P Parker, Ziga Ude, Celine J Marmion
Page
of 9
Search research articles
Search
Showing results (31-40 of 87) with videos related to
Sort By:
Page
of 9
Chemical Reviews
|
January 15, 2019
Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Reece G Kenny, Celine J Marmion
The British Journal of Ophthalmology
|
February 1, 1976
A clinical evaluation of the applanation pneumatonograph
M R Jain, V J Marmion
Journal of Neural Transmission (Vienna, Austria : 1996)
|
April 24, 2017
α-Synuclein nonhuman primate models of Parkinson's disease
David J Marmion, Jeffrey H Kordower
Journal of the Royal Society of Medicine
|
May 2, 2002
The death of Claudius
V J Marmion, T E J Wiedemann
Modern Problems in Ophthalmology
|
January 1, 1976
Genetic correlation of diabetic exudative retinopathy
V J Marmion, S Yurdakul, E A Keely
Chemical Communications (Cambridge, England)
|
November 4, 2009
A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity
Darren Griffith, Maria P Morgan, Celine J Marmion
Anti-Cancer Agents in Medicinal Chemistry
|
April 13, 2010
Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics
Darren Griffith, James P Parker, Celine J Marmion
Journal of Neural Transmission (Vienna, Austria : 1996)
|
October 6, 2021
A historical review of multiple system atrophy with a critical appraisal of cellular and animal models
David J Marmion, Wouter Peelaerts, Jeffrey H Kordower
Chemical Communications (Cambridge, England)
|
September 21, 2002
Ruthenium(III) readily abstracts NO from L-arginine, the physiological precursor to NO, in the presence of H2O2. A remarkably simple model system for NO synthases
C J Marmion, T Murphy, K B Nolan
Metallomics : Integrated Biometal Science
|
November 17, 2015
Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer
James P Parker, Ziga Ude, Celine J Marmion
Page
of 9